Jonathan G. Drachman's Insider Trades & SAST Disclosures
Jonathan G. Drachman's most recent trade in Harpoon Therapeutics Inc was a trade of 23,000 Director Stock Option (Right to Buy) done . Disclosure was reported to the exchange on June 22, 2023.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Jonathan G. Drachman.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Harpoon Therapeutics Inc | Jonathan G. Drachman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2023 | 23,000 | 23,000 | - | - | Director Stock Option (Right to Buy) | |
| Neoleukin Therapeutics Inc | Jonathan G. Drachman | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Aug 2022 | 350,000 | 350,000 | - | - | Stock Option (Right to Buy) | |
| Harpoon Therapeutics Inc | Jonathan G. Drachman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2022 | 10,167 | 10,167 | - | - | Director Stock Option (Right to Buy) | |
| Neoleukin Therapeutics Inc | Jonathan G. Drachman | Director, President and CEO | Purchase of securities on an exchange or from another person at price $ 6.11 per share. | 24 Aug 2021 | 100,000 | 2,348,686 (4%) | 0% | 6.1 | 611,100 | Common Stock |
| Neoleukin Therapeutics Inc | Jonathan G. Drachman | Director, President and CEO | Purchase of securities on an exchange or from another person at price $ 6.45 per share. | 24 Aug 2021 | 25,000 | 25,000 (0%) | 0% | 6.4 | 161,225 | Common Stock |
| Neoleukin Therapeutics Inc | Jonathan G. Drachman | Director, President and CEO | Purchase of securities on an exchange or from another person at price $ 6.45 per share. | 24 Aug 2021 | 25,000 | 25,000 (0%) | 0% | 6.4 | 161,225 | Common Stock |
| Neoleukin Therapeutics Inc | Jonathan G. Drachman | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Aug 2021 | 400,000 | 400,000 | - | - | Stock Option (Right to Buy) | |
| Neoleukin Therapeutics Inc | Jonathan G. Drachman | Director, President and CEO | Purchase of securities on an exchange or from another person at price $ 9.48 per share. | 03 Jun 2021 | 40,000 | 2,238,686 (4%) | 0% | 9.5 | 379,272 | Common Stock |
| Neoleukin Therapeutics Inc | Jonathan G. Drachman | Director, President and CEO | Purchase of securities on an exchange or from another person at price $ 9.61 per share. | 03 Jun 2021 | 10,000 | 2,248,686 (4%) | 0% | 9.6 | 96,082 | Common Stock |
| Neoleukin Therapeutics Inc | Jonathan G. Drachman | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Aug 2020 | 420,000 | 420,000 | - | - | Stock Option (Right to Buy) | |
| Harpoon Therapeutics Inc | Jonathan G. Drachman | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 May 2020 | 10,167 | 10,167 | - | - | Director Stock Option (Right to Buy) | |
| Harpoon Therapeutics Inc | Jonathan G. Drachman | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 May 2020 | 2,880 | 2,880 | - | - | Director Stock Option (Right to Buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges